keyword
MENU ▼
Read by QxMD icon Read
search

Icer

keyword
https://www.readbyqxmd.com/read/28914440/olaratumab-in-combination-with-doxorubicin-for-the-treatment-of-advanced-soft-tissue-sarcoma-an-evidence-review-group-perspective-of-a-national-institute-for-health-and-care-excellence-single-technology-appraisal
#1
REVIEW
Irina A Tikhonova, Tracey Jones-Hughes, James Dunham, Fiona C Warren, Sophie Robinson, Peter Stephens, Martin Hoyle
The manufacturer of olaratumab (Lartruvo(®)), Eli Lilly & Company Limited, submitted evidence for the clinical and cost effectiveness of this drug, in combination with doxorubicin, for untreated advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy, as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal process. The Peninsula Technology Assessment Group, commissioned to act as the Evidence Review Group (ERG), critically reviewed the company's submission...
September 15, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28914229/clinical-effectiveness-and-cost-effectiveness-of-beta-interferon-and-glatiramer-acetate-for-treating-multiple-sclerosis-systematic-review-and-economic-evaluation
#2
G J Melendez-Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, Rachel Court, Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell, Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli, Hannah Fraser, Aileen Clarke
BACKGROUND: At the time of publication of the most recent National Institute for Health and Care Excellence (NICE) guidance [technology appraisal (TA) 32] in 2002 on beta-interferon (IFN-β) and glatiramer acetate (GA) for multiple sclerosis, there was insufficient evidence of their clinical effectiveness and cost-effectiveness. OBJECTIVES: To undertake (1) systematic reviews of the clinical effectiveness and cost-effectiveness of IFN-β and GA in relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS) compared with best supportive care (BSC) and each other, investigating annualised relapse rate (ARR) and time to disability progression confirmed at 3 months and 6 months and (2) cost-effectiveness assessments of disease-modifying therapies (DMTs) for CIS and RRMS compared with BSC and each other...
September 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28910342/home-modification-to-reduce-falls-at-a-health-district-level-modeling-health-gain-health-inequalities-and-health-costs
#3
Nick Wilson, Giorgi Kvizhinadze, Frank Pega, Nisha Nair, Tony Blakely
BACKGROUND: There is some evidence that home safety assessment and modification (HSAM) is effective in reducing falls in older people. But there are various knowledge gaps, including around cost-effectiveness and also the impacts at a health district-level. METHODS AND FINDINGS: A previously established Markov macro-simulation model built for the whole New Zealand (NZ) population (Pega et al 2016, Injury Prevention) was enhanced and adapted to a health district level...
2017: PloS One
https://www.readbyqxmd.com/read/28904528/access-criteria-for-anti-tnf-agents-in-spondyloarthritis-influence-on-comparative-1-year-cost-effectiveness-estimates
#4
Stephanie Harvard, Daphne Guh, Nick Bansback, Pascal Richette, Alain Saraux, Bruno Fautrel, Aslam Anis
BACKGROUND: Anti-tumor necrosis factor (anti-TNF) agents are an effective, but costly, treatment for spondyloarthritis (SpA). Worldwide, multiple sets of access criteria aim to restrict anti-TNF therapy to patients with specific clinical characteristics, yet the influence of access criteria on anti-TNF cost-effectiveness is unknown. Our objective was to use data from the DESIR cohort, a prospective study of early SpA patients in France, to determine whether the French anti-TNF access criteria are the most cost-effective in that setting relative to other potential restrictions...
2017: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/28902880/cost-and-cost-effectiveness-of-a-school-based-education-program-to-reduce-salt-intake-in-children-and-their-families-in-china
#5
Xian Li, Stephen Jan, Lijing L Yan, Alison Hayes, Yunbo Chu, Haijun Wang, Xiangxian Feng, Wenyi Niu, Feng J He, Jun Ma, Yanbo Han, Graham A MacGregor, Yangfeng Wu
OBJECTIVE: The School-based Education Program to Reduce Salt Intake in Children and Their Families study was a cluster randomized control trial among grade five students in 28 primary schools and their families in Changzhi, China. It achieved a significant effect in lowering systolic blood pressure (SBP) in all family adults by 2.3 mmHg and in elderlies (aged > = 60 years) by 9.5 mmHg. The aim of this study was to assess the cost-effectiveness of this salt reduction program. METHODS: Costs of the intervention were assessed using an ingredients approach to identify resource use...
2017: PloS One
https://www.readbyqxmd.com/read/28901346/-procurement-of-medical-devices-based-on-cost-effectiveness-data
#6
Sabrina Trippoli
The field of medical devices is characterized by a paucity of cost-effectiveness data that support their use. In this context, we have proposed a project based on the calculation of net monetary benefit (NMB) for each product subjected to procurement through tenders. This project consists of two steps: 1) calculation of NMB; 2) calculation of a value-based score to be used in the process of procurement and tendering. The NMB is defined as follows: NMB per patient= (monetary threshold of WTP) x (QALYs per patient) - (treatment cost per patient); WTP= willingness to pay]...
September 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/28899625/cost-effectiveness-of-hpv-vaccination-in-the-context-of-high-cervical-cancer-incidence-and-low-screening-coverage
#7
Triin Võrno, Katrin Lutsar, Anneli Uusküla, Lee Padrik, Terje Raud, Rainer Reile, Oliver Nahkur, Raul-Allan Kiivet
BACKGROUND: Estonia has high cervical cancer incidence and low screening coverage. We modelled the impact of population-based bivalent, quadrivalent or nonavalent HPV vaccination alongside cervical cancer screening. METHODS: A Markov cohort model of the natural history of HPV infection was used to assess the cost-effectiveness of vaccinating a cohort of 12-year-old girls with bivalent, quadrivalent or nonavalent vaccine in two doses in a national, school-based vaccination programme...
September 9, 2017: Vaccine
https://www.readbyqxmd.com/read/28894850/cost-effectiveness-of-breast-cancer-screening-in-turkey-a-developing-country-results-from-bah%C3%A3-e%C3%A5-ehir-mammography-screening-project
#8
Vahit Özmen, Sibel Ö Gürdal, Neslihan Cabioğlu, Beyza Özcinar, A Nilüfer Özaydın, Arda Kayhan, Erkin Arıbal, Cennet Sahin, Pınar Saip, Oğuzhan Alagöz
OBJECTIVE: We used the results from the first three screening rounds of Bahcesehir Mammography Screening Project (BMSP), a 10-year (2009-2019) and the first organized population-based screening program implemented in a county of Istanbul, Turkey, to assess the potential cost-effectiveness of a population-based mammography screening program in Turkey. MATERIALS AND METHODS: Two screening strategies were compared: BMSP (includes three biennial screens for women between 40-69) and Turkish National Breast Cancer Registry Program (TNBCRP) which includes no organized population-based screening...
July 2017: Eur J Breast Health
https://www.readbyqxmd.com/read/28881547/-health-economic-evaluation-of-bivalent-human-papilloma-virus-vaccine-in-china-based-on-the-dynamic-model
#9
X B Song, Q J Zhao, Z Zhou, Y Fang
Objective: This study aims to evaluate the prevention effect and cost-effectiveness of a prophylactic bivalent human papilloma virus (HPV) vaccine. Methods: A multiple health status dynamic model was developed, including natural history of diseases and prevention strategies. We built 19 prevention strategies including visual inspection with acetic acid/lugol's iodine (VIA/VILI) and/or 3 does prophylactic bivalent HPV vaccine administered to adolescent girls at the age of 15 years old every year under the assumption that vaccine coverage and screening coverage were 70%...
September 6, 2017: Zhonghua Yu Fang Yi Xue za Zhi [Chinese Journal of Preventive Medicine]
https://www.readbyqxmd.com/read/28880737/cost-effectiveness-of-osimertinib-in-the-uk-for-advanced-egfr-t790m-non-small-cell-lung-cancer
#10
Evelina Bertranou, Carolyn Bodnar, Viktor Dansk, Alastair Greystoke, Samuel Large, Matthew Dyer
AIM: This study presents the cost-utility analysis that was developed to inform the NICE health technology assessment of osimertinib versus platinum-based doublet chemotherapy (PDC) in patients with EGFR-T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed on epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. METHODS AND MATERIALS: A partitioned survival model with three health states (progression-free, progressed disease, and death) from a UK payer perspective and over lifetime (15 years) was developed...
September 7, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28880698/cost-effectiveness-of-a-chronic-pain-intervention-for-people-living-with-hiv-plwh
#11
Jessica S Merlin, Andrew O Westfall, Mallory O Johnson, Robert D Kerns, Matthew J Bair, Stefan Kertesz, Janet M Turan, Olivio J Clay, Joanna L Starrels, Meredith Kilgore
BACKGROUND: Chronic pain is a common, disabling, and costly comorbidity, particularly in people living with HIV (PLWH). We developed and pilot tested a pain self-management intervention for chronic pain tailored to PLWH called Skills TO Manage Pain (STOMP). OBJECTIVES: Given the additional resources needed to deliver STOMP in HIV clinical settings, an important objective of the pilot study was to assess not only STOMP's preliminary efficacy, but also its cost-effectiveness...
September 7, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28878573/cost-effectiveness-of-human-papillomavirus-vaccination-in-germany
#12
Oliver Damm, Johannes Horn, Rafael T Mikolajczyk, Mirjam E E Kretzschmar, Andreas M Kaufmann, Yvonne Deleré, Bernhard Ultsch, Ole Wichmann, Alexander Krämer, Wolfgang Greiner
BACKGROUND: The aim of this study was to assess the cost-effectiveness of human papillomavirus (HPV) vaccination in addition to the current cervical cancer screening programme in Germany using a dynamic transmission model. METHODS: Based on a mathematical model simulating the transmission dynamics and the natural history of HPV infection and associated diseases (cervical intraepithelial neoplasia, cervical cancer, and genital warts), we estimated the epidemiological and economic consequences of HPV vaccination with both the quadrivalent and bivalent vaccines...
2017: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/28875395/cost-effectiveness-of-orbital-atherectomy-compared-to-rotational-atherectomy-in-treating-patients-with-severely-calcified-coronary-artery-lesions-in-japan
#13
Jan B Pietzsch, Benjamin P Geisler, Fumiaki Ikeno
Compared to rotational atherectomy (RA), orbital atherectomy (OA) has been shown to decrease procedure failure and reintervention rates in the treatment of severely calcified coronary artery lesions. Our objective was to explore the cost-effectiveness of OA compared to RA in the Japanese healthcare system. A decision-analytic model calculated reintervention rates and consequent total 1-year costs. Effectiveness inputs were therapy-specific target lesion revascularization (TLR) rates and all-cause mortality, pooled from clinical studies...
September 5, 2017: Cardiovascular Intervention and Therapeutics
https://www.readbyqxmd.com/read/28873286/the-impact-of-asthma-on-the-cost-effectiveness-of-surgery-for-chronic-rhinosinusitis-with-nasal-polyps
#14
George A Scangas, Aaron K Remenschneider, Brooke M Su, Mark G Shrime, Ralph Metson
BACKGROUND: The objective of this work was to evaluate the impact of asthma on the cost-effectiveness profile of endoscopic sinus surgery (ESS) compared to medical therapy for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). METHODS: The study design consisted of a cohort-style Markov decision-tree cost utility analysis with a 35-year time horizon. Matched cohorts of CRSwNP patients with (n = 95) and without (n = 95) asthma who underwent ESS were compared with cohorts of patients from the national Medical Expenditures Survey Panel (MEPS) database who underwent medical management for chronic rhinosinusitis (CRS)...
September 5, 2017: International Forum of Allergy & Rhinology
https://www.readbyqxmd.com/read/28871898/cost-effectiveness-impacts-cancer-care-funding-decisions-in-british-columbia-canada-evidence-from-1998-to-2008
#15
Zahra Ismail, Stuart J Peacock, Laurel Kovacic, Jeffrey S Hoch
OBJECTIVES: The Priorities and Evaluation Committee (PEC) funding recommendations for new cancer drugs in British Columbia, Canada have been based on both clinical and economic evidence. The British Columbia Ministry of Health makes funding decisions. We assessed the association between cost-effectiveness of cancer drugs considered from 1998 to 2008 and the subsequent funding decisions. METHODS: All proposals submitted to the PEC between 1998 and 2008 were reviewed, and the association between cost-effectiveness and funding decisions was examined by (i) using logistic regression to test the hypothesis that interventions with higher incremental cost-effectiveness ratios (ICERs) have a lower probability of receiving a positive funding decision and (ii) using parametric and nonparametric tests to determine if a statistically significant difference exists between the mean cost-effectiveness of funded versus not funded proposals...
September 5, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28868661/cost-effectiveness-analysis-of-long-term-intermittent-self-catheterization-with-hydrophilic-coated-and-uncoated-catheters-in-patients-with-spinal-cord-injury-in-japan
#16
Toyohiko Watanabe, Shingo Yamamoto, Momokazu Gotoh, Tadanori Saitoh, Osamu Yokoyama, Tatsunori Murata, Masayuki Takeda
OBJECTIVES: To evaluate the cost effectiveness of disposable, hydrophilic-coated catheters in Japan. METHODS: A Markov decision model previously applied in a European study was used to evaluate the cost effectiveness of intermittent self-catheterization (ISC) with hydrophilic-coated catheters in Japanese spinal cord injury (SCI) patients suffering from chronic urinary retention from a lifetime perspective. To adjust the model to a Japanese setting, relevant Japanese data regarding the baseline risk of urinary tract infection (UTI), the average age at onset of SCI, costs, and general mortality were extracted from published literature, national statistics, or the opinions of Japanese experts...
September 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28862479/cost-effectiveness-analysis-of-dabigatran-versus-rivaroxaban-for-stroke-prevention-in-patients-with-non-valvular-atrial-fibrillation-using-real-world-evidence-in-elderly-us-medicare-beneficiaries
#17
Siyang Peng, Kristen A Deger, Anastasia Ustyugova, Pranav Gandhi, Nan Qiao, Cheng Wang, Anuraag R Kansal
OBJECTIVE: Dabigatran and rivaroxaban have been approved by the US FDA to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) patients. Newly published real-world evidence based on the US population found that elderly Medicare patients with NVAF treated with rivaroxaban experienced statistically significant increases in intracranial hemorrhage (ICH) and major extracranial bleeding, and statistically nonsignificant decreases in thromboembolic stroke and acute myocardial infarction (AMI) compared with dabigatran...
September 1, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28860832/a-cost-effectiveness-analysis-of-first-line-induction-and-maintenance-treatment-sequences-in-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-in-france
#18
Kaisa Taipale, Katherine B Winfree, Mark Boye, Mickael Basson, Ghassan Sleilaty, James Eaton, Rachel Evans, Christos Chouaid
BACKGROUND: Comparative effectiveness and cost-effectiveness data for induction-maintenance (I-M) sequences for the treatment of patients with nonsquamous non-small-cell lung cancer (nsqNSCLC) are limited because of a lack of direct evidence. This analysis aimed to compare the cost-effectiveness of I-M pemetrexed with those of other I-M regimens used for the treatment of patients with advanced nsqNSCLC in the French health-care setting. MATERIALS AND METHODS: A previously developed global partitioned survival model was adapted to the France-only setting by restricting treatment sequences to include 12 I-M regimens most relevant to France, and incorporating French costs and resource-use data...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28852531/transversus-abdominis-plane-block-with-liposomal-bupivacaine-compared-to-oral-opioids-alone-for-acute-postoperative-pain-after-laparoscopic-hysterectomy-for-early-endometrial-cancer-a-cost-effectiveness-analysis
#19
Brandon-Luke L Seagle, Emily S Miller, Anna E Strohl, Anna Hoekstra, Shohreh Shahabi
BACKGROUND: To determine the cost-effectiveness of transversus abdominis plane block with liposomal bupivacaine (TAP) compared to oral opioids alone for acute postoperative pain after laparoscopic hysterectomy for early endometrial cancer. METHODS: A cost-effectiveness analysis using a decision tree structure with a 30.5 day time-horizon was used to calculate incremental cost-effectiveness ratio (ICER) values per quality-adjusted life-year (QALY). Base-case costs, probabilities, and QALY values were identified from recently published all-payer national database studies, 2017 Medicare fee-schedules, randomized trials, institutional case series, or assumed, when published values were not available...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28852326/cost-effectiveness-analysis-of-a-universal-mass-vaccination-program-with-a-phid-cv-2-1-schedule-in-malaysia
#20
Xiao Jun Wang, Ashwini Saha, Xu-Hao Zhang
BACKGROUND: Currently, two pediatric pneumococcal conjugate vaccines are available in the private market of Malaysia-13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). This study aimed to evaluate the cost-effectiveness of a universal mass vaccination program with a PHiD-CV 2+1 schedule versus no vaccination or with a PCV13 2+1 schedule in Malaysia. METHODS: A published Markov cohort model was adapted to evaluate the epidemiological and economic consequences of programs with no vaccination, a PHiD-CV 2+1 schedule or a PCV13 2+1 schedule over a 10-year time horizon...
2017: Cost Effectiveness and Resource Allocation: C/E
keyword
keyword
15878
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"